forward-looking statements

This presentation contains certain forward-looking statements with respect to the business of Novocure and certain of its plans and objectives, including with respect to the development and commercialization of Tumor Treating Fields delivery systems, including Optune and the NovoTTF-100L System, for a number of oncology indications. These forward-looking statements can be identified in this presentation by the fact that they do not relate only to historical or current facts. Forward-looking statements often use words "expect", "intend", "anticipate", "plan", "may", "should", "would", "could" or other words of similar meaning. These statements are based on assumptions and assessments made by Novocure in light of industry experience and perception of historical trends, current conditions, expected future developments and other appropriate factors. By their nature, forward-looking statements involve risk and uncertainty, and Novocure’s performance and financial results could differ materially from those expressed or implied in these forward-looking statements due to general financial, economic, regulatory and political conditions as well as more specific risks and uncertainties facing Novocure such as those set forth in its Annual Report on Form 10-K filed February 27, 2020, or in subsequent filings with the U.S. Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described in this presentation. Novocure assumes no obligation to update or correct the information contained in this presentation, whether as a result of new information, future events or otherwise, except to the extent legally required.

The statements contained in this presentation are made as at the date of this presentation, unless some other time is specified in relation to them, and service of this presentation shall not give rise to any implication that there has been no change in the facts set out in this presentation since such date. Nothing contained in this presentation shall be deemed to be a forecast, projection or estimate of the future financial performance of Novocure, except where expressly stated.

As of the date of this presentation, Optune is FDA-approved for the treatment of adults with supratentorial glioblastoma, or GBM, and for the treatment of adults with malignant pleural mesothelioma (MPM) and its approval for other indications is not certain. Novocure can provide no assurances regarding market acceptance of Optune or NovoTTF-100L or their successful commercialization, and can provide no assurances regarding the company’s results of operations or financial condition in the future. This presentation is for informational purposes only and may not be relied upon in connection with the purchase or sale of any security.
striving to extend survival in some of the most aggressive forms of cancer
strengthening our foundation for growth

- 14,000+ patients treated globally
- Four indications in late-stage pipeline
- 180+ issued patents and pending patent applications globally
- $326 million cash on hand*

*Cash, cash equivalents and short-term investments as of December 31, 2019
like gravity and magnetic fields, electric fields exert forces at a distance

**GRAVITATIONAL FIELDS**
exert force on masses

**MAGNETIC FIELDS**
exert force on iron & other magnets

**ELECTRIC FIELDS**
exert force on charges & polarized molecules

---

Earth

Magnet

Charged Plates

---

© Novocure 2020
mitotic spindle disruption has been observed in every cancer cell line tested

CONTROL

TUMOR TREATING FIELDS

Non-small cell lung cancer cell line. Blue staining is DAPI, highlighting DNA. Red staining is for pH3, highlighting DNA binding proteins. Green staining is for tubulin, highlighting the mitotic spindle. Novocure data on file.
therapy is frequency-tuned to target dividing cancer cells
growing evidence supports broad applicability in combination with certain other cancer therapies

**TUMOR TREATING FIELDS**

**WITH RADIATION THERAPY**

Tumor Treating Fields increased sensitivity to radiation therapy and inhibited DNA damage repair mechanisms in glioblastoma cells

**WITH CERTAIN CHEMOTHERAPIES**

*In vitro* dose-response effect of paclitaxel alone and in combination with Tumor Treating Fields in Lewis lung carcinoma cells

**WITH CERTAIN IMMUNOTHERAPIES**

Tumor Treating Fields in combination with anti-PD-1 were therapeutically effective *in vivo* in Lewis lung carcinoma cells

---

1. *p < 0.05, **p < 0.001*, Kim, E.H., et al. OncoGtaret 2016 Sep 20; 7(S8): 62267–62270
Tumor Treating Fields delivery systems FDA approved for GBM and MPM

**DELIVERY SYSTEM CONSISTS OF ELECTRIC FIELD GENERATOR AND TRANSDUCER ARRAYS**

The Optune® delivery system for GBM*

![Image of the Optune® delivery system for GBM]

**CONTINUOUS USE THERAPY INTEGRATED INTO PATIENT’S DAILY LIFE**

The NovoTTF-100L delivery system for MPM**

![Image of the NovoTTF-100L delivery system for MPM]

* Approved in the U.S. through the Premarket Authorization (PMA) Pathway
** Approved in the U.S. through the HDE pathway

GBM: glioblastoma
MPM: malignant pleural mesothelioma

© Novocure 2020
proven to provide long-term quality survival to patients with newly diagnosed GBM

Overall survival (5-year survival analysis)\(^{1,2}\)

- **Optune + TMZ (n=466)**
  - Median OS from randomization (months): 20.9
  - Log-rank P-value: <0.001
  - HR (95% CI): 0.63 (0.53-0.76)
  - Median OS from diagnosis (months): 24.5

- **TMZ alone (n=229)**
  - Median OS from randomization (months): 16.0
  - Log-rank P-value: <0.001
  - HR (95% CI): 0.76 (0.63-0.93)
  - Median OS from diagnosis (months): 19.8

\(\text{Probability of Survival} \quad \text{Optune + TMZ} \quad 43\% \quad \text{Optune + TMZ} \quad 13\% \quad \text{TMZ alone} \quad 31\% \quad \text{TMZ alone} \quad 5\%\)

\(\text{2-year overall survival} \quad \text{5-year overall survival}\)

Overall Survival (months)

---

**5-year survival analysis was published in JAMA, December 2017**

---


---

**CATEGORY**

1

**PART OF A NATIONAL COMPREHENSIVE CANCER NETWORK (NCCN)**

**CATEGORY 1 RECOMMENDATION FOR NEWLY DIAGNOSED GBM**

The updated NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Central Nervous System Cancers now include alternating electric field therapy (Optune) in combination with temozolomide (TMZ) following maximal safe resection and standard brain radiation therapy with concurrent TMZ as Category 1 recommended treatment option for patients with newly diagnosed supratentorial glioblastoma (GBM) and good performance status.* There is uniform NCCN consensus for this recommendation based on high-level evidence (Category 1).
more time on Optune predicted increased significant survival benefit in GBM

86% of patients received a survival benefit from Optune because they used it more than half the time (n=388/450)

---

Median OS by percentage of monthly time on Optune*

<table>
<thead>
<tr>
<th>Percentage of Monthly Time on Optune</th>
<th>Median OS (months)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>90%-100% (n=43) 22-24 hours/day¹</td>
<td>25</td>
<td>&lt;0.05¹</td>
</tr>
<tr>
<td>70%-90% (n=257) 17-22 hours/day¹</td>
<td>22</td>
<td>&lt;0.05¹</td>
</tr>
<tr>
<td>60%-70% (n=46) 14-17 hours/day¹</td>
<td>20</td>
<td>&lt;0.05¹</td>
</tr>
<tr>
<td>50%-60% (n=42) 12-14 hours/day¹</td>
<td>18</td>
<td>&lt;0.05¹</td>
</tr>
<tr>
<td>0% (n=229) TMZ alone</td>
<td>16</td>
<td></td>
</tr>
</tbody>
</table>

TMZ, temozolomide

¹ Based on amount of time Optune was turned on and providing therapy over the course of a month.

This data reflects the average patient usage of Optune for the first 6 months of treatment (months 1-6). Approximation, based on monthly usage.

¹vs TMZ alone.

patients treated with Optune for newly diagnosed GBM maintained quality of life over time

QoL over 12 months²,¹³

- **HCP-reported**
  - Karnofsky Performance Score

- **Patient-reported**
  - Global Health Status

<table>
<thead>
<tr>
<th></th>
<th>Optune + TMZ</th>
<th>TMZ alone</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean NPS</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12 Months</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>Mean HRQoL Score</th>
</tr>
</thead>
<tbody>
<tr>
<td>Baseline</td>
<td></td>
</tr>
<tr>
<td>12 Months</td>
<td></td>
</tr>
</tbody>
</table>

TMZ, temozolomide

FDA approved NovoTTF-100L for mesothelioma*, our first torso indication, based on STELLAR results

97% Responded to treatment with NovoTTF-100L + chemo
57% Had stable disease
40% Had a partial response

*unresectable, locally advanced or metastatic, malignant pleural mesothelioma (MPM) to be used together with standard chemotherapy (pemetrexed and platinum-based chemotherapy)

The NovoTTF-100L System was approved by FDA under the Humanitarian Device Exemption (HDE) pathway in May 2019.

Caution: Federal law restricts the NovoTTF-100L System to sale by or on the order of a physician. Humanitarian Device. Authorized by Federal Law for use in the treatment of adult patients with unresectable, locally advanced or metastatic, malignant pleural mesothelioma concurrently with pemetrexed and platinum-based chemotherapy. The effectiveness of this device for this use has not been demonstrated.

STELLAR results published in The Lancet Oncology, October 2019

© Novocure 2020
direct-to-patient distribution model

1. Prescription order
2. Patient start
3. Active patient
4. Therapy usage

- Novocure Device Support Specialist delivers device and trains patient
- Novocure provides supplies and 24/7 support for patients
- Novocure bills third-party payers and patients a single fee per month of therapy
continued commercial execution

global net revenues (USD in millions)

$13.1, $17.9, $21.7, $30.2, $34.9, $38.4, $50.1, $53.7, $52.1, $61.5, $64.8, $69.7, $73.3, $86.7, $92.1, $99.2


42% REVENUE GROWTH 2019 VERSUS 2018

20 CONSECUTIVE QUARTERS OF ACTIVE PATIENT GROWTH SINCE INITIAL PRESENTATION OF EF-14 DATA
multiple levers to drive revenue growth

**UNITED STATES**
- 1,002  total prescriptions in the period
- 1,952  active patients at period end
- 263m   contracted GBM lives at period end

**EMEA**
- 285    total prescriptions in the period
- 765    active patients at period end
- 19m    contracted GBM lives at period end

**JAPAN**
- 93     total prescriptions in the period
- 192    active patients at period end
- 127m   contracted GBM lives at period end

Information above as of December 31, 2019
Global net revenues include Greater China revenue
additional revenue from collaboration with Zai Lab in Greater China

- Optune for GBM launched in Hong Kong in February 2019
- Phase 2 pilot trial in gastric cancer initiated in January 2020
- Marketing Authorization Application accepted by Chinese NMPA and under review

Greater China includes mainland China, Hong Kong, Macau and Taiwan
financial strength funds investments in innovation

REINFORCING LOOP OF GROWTH
• Growing GBM business establishes solid financial foundation and generates operating leverage
• Strong balance sheet and cash position provide broad flexibility to execute on clinical and product development
• Well-positioned to capture significant TAM expansion opportunity

Global Net Revenues ($m)

<table>
<thead>
<tr>
<th>Year</th>
<th>FY 2016</th>
<th>FY 2017</th>
<th>FY 2018</th>
<th>FY 2019</th>
</tr>
</thead>
<tbody>
<tr>
<td>Value</td>
<td>$83</td>
<td>$177</td>
<td>$248</td>
<td>$351</td>
</tr>
</tbody>
</table>

R&D Expenses

<table>
<thead>
<tr>
<th>Year</th>
<th>FY 2016</th>
<th>FY 2017</th>
<th>FY 2018</th>
<th>FY 2019</th>
</tr>
</thead>
<tbody>
<tr>
<td>Value</td>
<td>$41</td>
<td>$38</td>
<td>$51</td>
<td>$79</td>
</tr>
</tbody>
</table>

SG&A Expense Ratio

<table>
<thead>
<tr>
<th>Year</th>
<th>FY 2016</th>
<th>FY 2017</th>
<th>FY 2018</th>
<th>FY 2019</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ratio</td>
<td>133%</td>
<td>69%</td>
<td>61%</td>
<td>53%</td>
</tr>
</tbody>
</table>

Cash Flow from Operations ($m)

<table>
<thead>
<tr>
<th>Year</th>
<th>FY 2016</th>
<th>FY 2017</th>
<th>FY 2018</th>
<th>FY 2019</th>
</tr>
</thead>
<tbody>
<tr>
<td>Value</td>
<td>$(108)</td>
<td>$(33)</td>
<td>$(2)</td>
<td>$27</td>
</tr>
</tbody>
</table>

1 SG&A Expense Ratio equals total selling, general and administrative expenses divided by total net revenues in the period
2 Cash on Hand equals sum of cash, cash equivalents and short-term investments in the period
### q4 2019 selected financial highlights

<table>
<thead>
<tr>
<th>U.S. DOLLARS IN THOUSANDS</th>
<th>Q4 2019</th>
<th>Q4 2018</th>
<th>% CHANGE</th>
<th>FY 2019</th>
<th>FY 2018</th>
<th>% CHANGE</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Net revenues</strong></td>
<td>$99,234</td>
<td>$69,674</td>
<td>42%</td>
<td>$351,318</td>
<td>$248,069</td>
<td>42%</td>
</tr>
<tr>
<td><strong>Cost of revenues</strong></td>
<td>24,786</td>
<td>23,028</td>
<td>8%</td>
<td>88,606</td>
<td>80,048</td>
<td>11%</td>
</tr>
<tr>
<td><strong>Gross profit</strong></td>
<td>74,448</td>
<td>46,646</td>
<td>60%</td>
<td>262,712</td>
<td>168,021</td>
<td>56%</td>
</tr>
<tr>
<td>Research, development and clinical trials</td>
<td>23,741</td>
<td>15,034</td>
<td>58%</td>
<td>79,003</td>
<td>50,574</td>
<td>56%</td>
</tr>
<tr>
<td>Sales and marketing</td>
<td>26,804</td>
<td>21,208</td>
<td>26%</td>
<td>96,675</td>
<td>77,663</td>
<td>24%</td>
</tr>
<tr>
<td>General and administrative</td>
<td>23,751</td>
<td>19,068</td>
<td>25%</td>
<td>87,948</td>
<td>73,456</td>
<td>20%</td>
</tr>
<tr>
<td><strong>Total operating costs and expenses</strong></td>
<td>74,296</td>
<td>55,310</td>
<td>34%</td>
<td>263,626</td>
<td>201,693</td>
<td>31%</td>
</tr>
<tr>
<td><strong>Operating income (loss)</strong></td>
<td>152</td>
<td>(8,664)</td>
<td>-102%</td>
<td>(914)</td>
<td>(33,672)</td>
<td>-97%</td>
</tr>
<tr>
<td>Financial expenses, net</td>
<td>1,744</td>
<td>2,160</td>
<td>-19%</td>
<td>7,910</td>
<td>12,270</td>
<td>-36%</td>
</tr>
<tr>
<td>Income (loss) before income taxes</td>
<td>(1,592)</td>
<td>(10,824)</td>
<td>-85%</td>
<td>(8,824)</td>
<td>(45,942)</td>
<td>-81%</td>
</tr>
<tr>
<td>Income taxes</td>
<td>(5,852)</td>
<td>4,807</td>
<td>-222%</td>
<td>(1,594)</td>
<td>17,617</td>
<td>-109%</td>
</tr>
<tr>
<td><strong>Net income (loss)</strong></td>
<td>$4,260</td>
<td>$(15,631)</td>
<td>-127%</td>
<td>$(7,230)</td>
<td>$(63,559)</td>
<td>-89%</td>
</tr>
<tr>
<td>Cash, cash equivalents and short-term investments</td>
<td>$326,090</td>
<td>$245,878</td>
<td>33%</td>
<td>$326,090</td>
<td>$245,878</td>
<td>33%</td>
</tr>
</tbody>
</table>
broadly applicable mechanism of action

CANCERS OF THE BRAIN
- 2 marketed indications
- 1 indication in development
- 4 additional cancer types with preclinical evidence

CANCERS OF THE TORSO
- 1 marketed indication
- 1 indication in development
- 2 additional cancer types with preclinical evidence

CANCERS OF THE ABDOMEN
- 0 marketed indications
- 4 indications in development
- 4 additional cancer types with preclinical evidence
efficacy suggested in all phase 2 pilot studies

NON-SMALL CELL LUNG CANCER PHASE 2 PILOT STUDY¹

13.8 months median overall survival vs. 8.3 months in pemetrexed-alone historical control

PANCREATIC CANCER PHASE 2 PILOT STUDY²

median overall survival not reached vs. 8.5 mos. in nab-paclitaxel + gemcitabine historical control

OVARIAN CANCER PHASE 2 PILOT STUDY³

median overall survival not reached vs. 13.2 mos. in paclitaxel-alone historical control


ongoing METIS trial in brain metastases

METIS PHASE 3 PIVOTAL, OPEN-LABEL, RANDOMIZED TRIAL DESIGN

- 270 patients with 12 months follow-up
- Primary endpoint: time to intracranial progression
- Designed to detect hazard ratio of 0.57 (+6 mos. in time to progression)
- Final data anticipated in 2021

---


- patientforward
ongoing LUNAR trial in non-small cell lung cancer

LUNAR PHASE 3 PIVOTAL, OPEN-LABEL, RANDOMIZED TRIAL DESIGN

- 534 patients with 18 months follow-up
- Primary endpoint: overall survival
- Designed to detect hazard ratio of 0.75 (+5 mos. in OS)
- Final data anticipated in 2022

---

ongoing PANova-3 trial in pancreatic cancer

**PANOVA-3 Phase 3 Pivotal, Open-Label, Randomized Trial Design¹**

- 556 patients with 18 months follow-up
- Primary endpoint: overall survival
- Designed to detect hazard ratio of 0.75 (+5 mos. in OS)
- Final data anticipated in 2022

---

ongoing INNOVATE-3 trial in ovarian cancer

INNOVATE-3 PHASE 3 PIVOTAL, OPEN-LABEL, RANDOMIZED TRIAL DESIGN

- 540 patients with 18 months follow-up
- Primary endpoint: overall survival
- Designed to detect hazard ratio of 0.75 (+4 mos. in OS)
- Final data anticipated in 2024

---

in vitro data informed HEPANOVA phase 2 pilot trial design in liver cancer

EFFICACY OF TTFIELDS AND SORAFENIB COMBINATION TREATMENT

HEPANOVA PHASE 2 PILOT TRIAL DESIGN

- 25 patients with 6 months follow-up
- Designed to detect an overall radiological response rate of 20% vs. 4.5% in historical controls
- Final data anticipated in 2021


first phase 2 pilot trial in gastric cancer initiated in Greater China in partnership with Zai Lab

EFFICACY OF TTFields AND FOLFOX COMBINATION TREATMENT\(^1\)

The overall effect of TTFields/FOLFOX combination treatment was significantly higher versus either treatment alone for the AGS cell line.

* \(P<0.05\), ** \(P<0.01\), *** \(P<0.001\)


---

PHASE 2 PILOT TRIAL DESIGN EVALUATING SAFETY AND EFFICACY OF TTFields AND XELOX CHEMOTHERAPY IN GASTRIC CANCER

- Screening and baseline evaluation
- TTFields + XELOX chemotherapy q3w
- CT/MRI scan q9w until progression
- Survival follow-up q12w

- 28 patients with 12 months follow-up
- Designed to detect investigator-assessed objective response rate per RECIST 1.1
late-stage pipeline creates potential for substantial market expansion

= 5,000 cases diagnosed annually in the U.S.

- Glioblastoma (GBM)
- Mesothelioma (MPM)
- Brain metastases from non-small cell lung cancer
- Non-small cell lung cancer
- Pancreatic cancer
- Ovarian cancer

Today

~3 Years

~5 Years
product innovation intended to improve efficacy and patient ease of use
potential to improve efficacy through extended time on therapy and increased intensity

TIME ON THERAPY IN EF-14 STUDY\(^1\)

<table>
<thead>
<tr>
<th>Percentage of Monthly Time on Optune</th>
<th>Median OS, months</th>
</tr>
</thead>
<tbody>
<tr>
<td>90%-100% (n=43) 22-24 hours/day(^1)</td>
<td>25 months, (P=0.05)</td>
</tr>
<tr>
<td>70%-90% (n=257) 17-22 hours/day(^1)</td>
<td>22 months, (P=0.05)</td>
</tr>
<tr>
<td>60%-70% (n=46) 14-17 hours/day(^1)</td>
<td>20 months, (P=0.05)</td>
</tr>
<tr>
<td>50%-60% (n=42) 12-14 hours/day(^1)</td>
<td>18 months, (P=0.05)</td>
</tr>
<tr>
<td>0% (n=229) TMZ alone</td>
<td>16 months</td>
</tr>
</tbody>
</table>

\(^1\) Based on amount of time Optune was used and providing therapy over the course of 1 month. This data reflects the average patient usage of Optune for the first 6 months of treatment (months 1-6). Approximations based on monthly usage. \(n=911\) TMZ alone.


current product development programs

- 2nd generation torso device
- Flexible torso array
- Frequency manipulation
- High intensity head array
- Transducer array layout planning software

ONGOING TECHNOLOGY INNOVATION WITH 33 NEW PATENT APPLICATIONS IN 2019
striving to extend survival in some of the most aggressive forms of cancer
NovoTTF-100L™ System and Optune® indications for use and important safety information

INDICATIONS

• Optune is intended as a treatment for adult patients (22 years of age or older) with histologically-confirmed glioblastoma multiforme (GBM).
• Optune with temozolomide is indicated for the treatment of adult patients with newly diagnosed, supratentorial glioblastoma following maximal debulking surgery, and completion of radiation therapy together with concomitant standard of care chemotherapy.
• For the treatment of recurrent GBM, Optune is indicated following histologically- or radiologically-confirmed recurrence in the supratentorial region of the brain after receiving chemotherapy. The device is intended to be used as a monotherapy, and is intended as an alternative to standard medical therapy for GBM after surgical and radiation options have been exhausted.
• The NovoTTF-100L System is indicated for the treatment of adult patients with unresectable, locally advanced or metastatic, malignant mesothelioma (MPM) to be used concurrently with pemetrexed and platinum-based chemotherapy.

CONTRAINDICATIONS

• Do not use Optune in patients with GBM with an implanted medical device, a skull defect (such as, missing bone with no replacement), or bullet fragments. Use of Optune together with skull defects or bullet fragments has not been tested and may possibly lead to tissue damage or render Optune ineffective. Do not use the NovoTTF-100L System in patients with MPM with implantable electronic medical devices such as pacemakers or implantable automatic defibrillators, etc.
• Use of Optune for GBM or the NovoTTF-100L System for MPM together with implanted electronic devices has not been tested and may lead to malfunctioning of the implanted device.
• Do not use Optune for GBM or the NovoTTF-100L System for MPM in patients known to be sensitive to conductive hydrogels. Skin contact with the gel used with Optune and the NovoTTF-100L System may commonly cause increased redness and itching, and may rarely lead to severe allergic reactions such as shock and respiratory failure.
NovoTTF-100L™ System and Optune® indications for use and important safety information

WARNINGS AND PRECAUTIONS

• Optune and the NovoTTF-100L System can only be prescribed by a healthcare provider that has completed the required certification training provided by Novocure®.

• The most common (≥10%) adverse events involving Optune in combination with chemotherapy in patients with GBM were thrombocytopenia, nausea, constipation, vomiting, fatigue, convulsions, and depression.

• The most common (≥10%) adverse events related to Optune treatment alone in patients with GBM were medical device site reaction and headache. Other less common adverse reactions were malaise, muscle twitching, and falls related to carrying the device.

• The most common (≥10%) adverse events involving the NovoTTF-100L System in combination with chemotherapy in patients with MPM were anemia, constipation, nausea, asthenia, chest pain, fatigue, device skin reaction, pruritus, and cough.

• Other potential adverse effects associated with the use of the NovoTTF-100L System include: treatment related skin toxicity, allergic reaction to the plaster or to the gel, electrode overheating leading to pain and/or local skin burns, infections at sites of electrode contact with the skin, local warmth and tingling sensation beneath the electrodes, muscle twitching, medical site reaction and skin breakdown/skin ulcer.

• If the patient has an underlying serious skin condition on the treated area, evaluate whether this may prevent or temporarily interfere with Optune treatment and the NovoTTF-100L System.

• Do not prescribe Optune or the NovoTTF-100L System for patients that are pregnant, you think might be pregnant or are trying to get pregnant, as the safety and effectiveness of the NovoTTF-100L System and Optune in these populations have not been established.

• Please go to Optune.com to see the Optune Instructions For Use (IFU) for complete information regarding the device’s indications, contraindications, warnings, and precautions.

Please go to Optune.com to see the NovoTTF-100L IFU for complete information regarding the device’s indications, contraindications, warnings, and precautions.
Appendix
we can leverage physics to fight cancer

AN ELECTRIC FIELD EXERTS FORCES ON CHARGED OBJECTS

TUMOR TREATING FIELDS USES ELECTRIC FIELDS TO DISRUPT CELL DIVISION

MISALIGNED TUBULINS INTERFERE WITH FORMATION OF MITOTIC SPINDLE

ALTERNATING ELECTRIC FIELDS DISRUPT CANCER CELL DIVISION

CANCER CELL DEATH

TUMOR TREATING FIELDS DESCRIBES ELECTRIC FIELDS THAT ALTERNATE 100,000 TO 300,000 TIMES PER SECOND TO TARGET CANCER CELLS
2019 accomplishments support future value creation

<table>
<thead>
<tr>
<th>Initiation of INNOVATE-3 clinical trial</th>
</tr>
</thead>
<tbody>
<tr>
<td>FDA approval of NovoTTF-100L for MPM under HDE pathway</td>
</tr>
<tr>
<td>Medicare coverage of Optune for newly diagnosed GBM</td>
</tr>
<tr>
<td>Marketing Authorization Application for GBM accepted in China</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Publications in <em>Red Journal</em> and <em>The Lancet Oncology</em></th>
</tr>
</thead>
<tbody>
<tr>
<td>265+ presentations at key medical congresses</td>
</tr>
<tr>
<td>$80 million cash added to the balance sheet*</td>
</tr>
</tbody>
</table>

GBM: glioblastoma; MPM: malignant pleural mesothelioma; HDE: humanitarian device exemption

*Cash, cash equivalents and short-term investments as of December 31, 2019 versus as of December 31, 2018

patientforward